NCT07491029

Brief Summary

The goal of this clinical study is to evaluate whether AI-based customized transcranial direct current stimulation (tDCS) using MR images is more effective than sham stimulation in improving finger motor function in patients with finger paralysis caused by subacute stroke. The main questions it aims to answer are:

  • Does AI-based customized tDCS improve finger motor function compared with sham stimulation?
  • What medical problems or adverse events occur when participants receive AI-based customized tDCS? Researchers will compare AI-based customized tDCS with sham stimulation (a look-alike stimulation that delivers no electrical current) to determine whether the intervention improves finger motor recovery in patients with subacute stroke.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
116

participants targeted

Target at P50-P75 for not_applicable

Timeline
18mo left

Started Apr 2026

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress8%
Apr 2026Dec 2027

First Submitted

Initial submission to the registry

March 16, 2026

Completed
8 days until next milestone

First Posted

Study publicly available on registry

March 24, 2026

Completed
1 month until next milestone

Study Start

First participant enrolled

April 30, 2026

Completed
1.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 31, 2027

Expected
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2027

Last Updated

March 24, 2026

Status Verified

March 1, 2026

Enrollment Period

1.3 years

First QC Date

March 16, 2026

Last Update Submit

March 19, 2026

Conditions

Keywords

tDCSstrokerehabilitationfinger paralysisupper extremitytranscranial direct current stimulationupper limb motor function

Outcome Measures

Primary Outcomes (1)

  • Fugl-Meyer Function Test

    The Fugl-Meyer Assessment (FMA) is a validated clinical scale used to evaluate sensorimotor recovery in patients with post-stroke hemiplegia based on Brunnstrom stages of motor recovery. Each item is scored on a 3-point scale (0 = cannot perform, 1 = performs partially, 2 = performs fully). In this study, the upper-extremity FMA will be used. The assessment includes items evaluating the shoulder, elbow, forearm, wrist, hand (fingers), coordination/speed, sensation, passive joint motion, and joint pain during passive movement, with a total score ranging from 0 to 126 points.

    Baseline, At 2 weeks from baseline

Secondary Outcomes (7)

  • Fugl-Meyer Function Test

    Baseline, At 1, 3, 4, 14 weeks from baseline

  • Wolf Motor Function Test

    Baseline, At 1, 2, 3, 4, 14 weeks from baseline

  • Box and Blocks Test

    Baseline, At 1, 2, 3, 4, 14 weeks from baseline

  • Korean version of Modified Barthel Index (K-MBI)

    Baseline, At 1, 2, 3, 4, 14 weeks from baseline

  • Grip Strength

    Baseline, At 1, 2, 3, 4, 14 weeks from baseline

  • +2 more secondary outcomes

Study Arms (2)

Experimental: AI-Based Customized tDCS

EXPERIMENTAL

Participants receive customized stimulation obtained from an individualized T1 MRI-based simulation of transcranial direct current stimulation for 30 minutes, once a day for 2 weeks, for a total of 10 sessions.

Device: AI-based Customized transcranial Direct Current Stimulation

Sham Comparator: sham tDCS

SHAM COMPARATOR

Participants receive sham stimulation for 30 minutes once daily for 2 weeks (10 sessions total). Electrodes are placed according to the AI-based customized montage, but no current is delivered (0 mA).

Device: Sham transcranial Direct Current Stimulation

Interventions

Transcranial direct current stimulation (2 mA for 30 minutes) will be delivered using electrode positions optimized by an AI-based simulation based on each participant's MR images to target the motor cortex.

Also known as: NEUROPHET tES LAB, NEUROPHET innk01-DW
Experimental: AI-Based Customized tDCS

Transcranial direct current stimulation (0 mA for 30 minutes) will be delivered using electrode positions optimized by an AI-based simulation based on each participant's MR images.

Also known as: NEUROPHET tES LAB, NEUROPHET innk01-DW
Sham Comparator: sham tDCS

Eligibility Criteria

Age19 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Participants must meet all of the following criteria to be eligible for this clinical trial:
  • Adults aged 19 years or older
  • Patients with stroke confirmed by brain imaging
  • Subacute stroke patients within 2 weeks to 3 months after stroke onset
  • Patients with unilateral upper-extremity paralysis
  • Upper-extremity Fugl-Meyer Assessment (FMA-UE, maximum score 66) score between 20 and 56
  • Participants who voluntarily provide written informed consent after receiving and understanding the study procedures and requirements

You may not qualify if:

  • Participants will be excluded if they meet any of the following criteria:
  • History of a condition affecting the function of the paralyzed arm
  • Inability to follow instructions or complete the study due to cognitive impairment or aphasia
  • Evidence of delirium, confusion, or other disorders of consciousness
  • Presence of uncontrolled medical or surgical conditions
  • Severe neurological disorders associated with major psychiatric conditions (e.g., major depressive disorder, schizophrenia, bipolar disorder, or dementia)
  • History of uncontrolled epilepsy (seizure disorder)
  • Contraindications to transcranial direct current stimulation (tDCS), including:
  • Scalp disease or metal materials at the electrode attachment site
  • Presence of a cardiac pacemaker or cochlear implant
  • Medical contraindications to MRI examination
  • Pregnant or breastfeeding women, or those planning pregnancy during the study period
  • Use of a stimulation device similar to the investigational device or participation in a related clinical study within the past 1 year
  • Individuals judged by the investigator to be medically or ethically unsuitable for participation in this clinical study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Severance Hospital

Seoul, South Korea

Location

MeSH Terms

Conditions

Stroke

Condition Hierarchy (Ancestors)

Cerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesVascular DiseasesCardiovascular Diseases

Study Officials

  • Deog Young Kim

    Department and Research Institute of Rehabilitation Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea

    STUDY CHAIR

Central Study Contacts

Soo Young Whang

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 16, 2026

First Posted

March 24, 2026

Study Start

April 30, 2026

Primary Completion (Estimated)

July 31, 2027

Study Completion (Estimated)

December 31, 2027

Last Updated

March 24, 2026

Record last verified: 2026-03

Data Sharing

IPD Sharing
Will not share

Locations